What is tgf b

Inhibition of pulmonary and skeletal metastasis by a transforming growth factor-beta type I receptor kinase inhibitor. Cancer Res ; 66 — Transforming growth factor-beta stimulates parathyroid hormone-related protein and osteolytic metastases via Smad and mitogen-activated protein kinase signaling pathways. TGF-beta inhibitors for the treatment of cancer. Expert Opin Investig Drugs ; 14 — Akhurst RJ. Large- and small-molecule inhibitors of transforming growth factor-beta signaling.

Curr Opin Investig Drugs ; 7 — Inhibitors of the TGF-beta superfamily and their clinical applications. Mini Rev Med Chem ; 6 — Inhibition of ALK5 as a new approach to treat liver fibrotic diseases. Drug News Perspect ; 19 — Therapeutic strategies against TGF-beta signaling pathway in hepatic fibrosis. Liver Int ; 26 :8— PubMed Google Scholar. Transforming growth factor-beta: a molecular target for the future therapy of glioblastoma. Curr Pharm Des ; 12 — Anti-TGF-beta strategies for the treatment of chronic liver disease.

Fibrogenesis in Crohn's disease. Am J Gastroenterol ; — Lim H, Zhu YZ. Role of transforming growth factor-beta in the progression of heart failure. Cell Mol Life Sci ; 63 — J Cell Physiol ; — Pharmacol Rep ; 58 — Wojtowicz-Praga S. Reversal of tumor-induced immunosuppression by TGF-beta inhibitors. Invest New Drugs ; 2 — Minimal effects on immune parameters following chronic anti-TGF-beta monoclonal antibody administration to normal mice.

Immunopharmacol Immunotoxicol ; 25 — Lifetime exposure to a soluble TGF-beta antagonist protects mice against metastasis without adverse side effects.

Topical application of a peptide inhibitor of transforming growth factor-beta1 ameliorates bleomycin-induced skin fibrosis. Recombinant soluble betaglycan is a potent and isoform-selective transforming growth factor-beta neutralizing agent. Biochem J ; Part 1 — Antitumor activity of a recombinant soluble betaglycan in human breast cancer xenograft. Cancer Res ; 62 — Progressive transforming growth factor beta1-induced lung fibrosis is blocked by an orally active ALK5 kinase inhibitor.

Konneh M. Tranilast, Kissei Pharmaceuticals. Idrugs ; 1 — Pfab T, Hocher B. Tranilast and hypertensive heart disease: further insights into mechanisms of an anti-inflammatory and anti-fibrotic drug. J Hypertens ; 22 — The inhibition mechanism of histamine release by N - 3,4-dimethoxycinnamoyl anthranilic acid.

Int Arch Allergy Appl Immunol ; 77 — Shioda H. Allergy ; 34 — Ann Allergy ; 53 — The mechanism involved in the inhibitory action of tranilast on collagen biosynthesis of keloid fibroblasts.

Jpn J Pharmacol ; 60 — Effect of tranilast, an anti-allergic drug, on the human keloid tissues. Nippon Yakurigaku Zasshi ; 99 — Tranilast, a selective inhibitor of collagen synthesis in human skin fibroblasts. J Biochem Tokyo ; — Int Arch Allergy Appl Immunol ; 95 — Inhibition by tranilast of collagen accumulation in hypersensitive granulomatous inflammation in vivo and of morphological changes and functions of fibroblasts in vitro.

Suppressive effects of tranilast on pulmonary fibrosis and activation of alveolar macrophages in mice treated with bleomycin: role of alveolar macrophages in the fibrosis. Jpn J Pharmacol ; 67 — Reduction in left ventricular messenger RNA for transforming growth factor beta 1 attenuates left ventricular fibrosis and improves survival without lowering blood pressure in the hypertensive TGR mRen2 27 Rat. Hypertension ; 36 — Inhibition of left ventricular fibrosis by tranilast in rats with renovascular hypertension.

J Hypertens ; 20 — Tranilast reduces mesenteric vascular collagen deposition and chymase-positive mast cells in experimental diabetes. J Diabetes Complicat ; 18 — Tranilast attenuates cardiac matrix deposition in experimental diabetes: role of transforming growth factor-beta.

Cardiovasc Res ; 65 — In vitro models of TGF-beta-induced fibrosis suitable for high-throughput screening of anti-fibrotic agents. Inhibition of PDGF- and TGF-beta 1-induced collagen synthesis, migration and proliferation by tranilast in vascular smooth muscle cells from spontaneously hypertensive rats.

Atherosclerosis ; — Inhibitory effect of tranilast on activation and transforming growth factor beta 1 expression in cultured rat stellate cells. Biochem Biophys Res Commun ; — Inhibitory effects of tranilast on expression of transforming growth factor-beta isoforms and receptors in injured arteries.

Tranilast prevents activation of transforming growth factor-beta system, leukocyte accumulation, and neointimal growth in porcine coronary arteries after stenting. Arterioscler Thromb Vasc Biol ; 22 — N -[3,4-dimethoxycinnamoyl]-anthranilic acid tranilast inhibits transforming growth factor-beta relesase and reduces migration and invasiveness of human malignant glioma cells.

Int J Cancer ; — Modulation of human monocyte activities by tranilast, SB , a compound demonstrating efficacy in restenosis. J Pharmacol Exp Ther ; — Tranilast attenuates vascular hypertrophy, matrix accumulation and growth factor overexpression in experimental diabetes. Diabetes Metab ; 29 4 Part 1 — Tranilast N -3,4-dimethoxycinamoyl anthranilic acid : a novel inhibitor of invasion-stimulating interaction between gastric cancer cells and orthotopic fibroblasts.

Anticancer Res ; 23 5A — Intervention with tranilast attenuates renal pathology and albuminuria in advanced experimental diabetic nephropathy. Nephron Physiol ; 95 :p83—p Tranilast attenuates structural and functional aspects of renal injury in the remnant kidney model.

J Am Soc Nephrol ; 15 — Tranilast prevents the progression of experimental diabetic nephropathy through suppression of enhanced extracellular matrix gene expression. Tranilast attenuates connective tissue growth factor-induced extracellular matrix accumulation in renal cells. Kidney Int ; 69 — Combination therapy with tranilast and angiotensin-converting enzyme inhibition provides additional renoprotection in the remnant kidney model.

Treatment of autoimmune neuroinflammation with a synthetic tryptophan metabolite. Science ; — Tranilast inhibits interleukin-1beta-induced monocyte chemoattractant protein-1 expression in rat mesangial cells.

Eur J Pharmacol ; — Long-term prospective pilot study with tranilast for the prevention of stricture progression in patients with Crohn's disease. Gut ; 56 — Sensitivity of scirrhous gastric cancer to 5-fluorouracil and the role of cancer cell-stromal fibroblast interaction. Oncol Rep ; 12 — Tranilast inhibits the proliferation of uterine leiomyoma cells in vitro through G1 arrest associated with the induction of p21 waf1 and p J Clin Endocrinol Metab ; 87 — Mouse genetic evidence that tranilast reduces smooth muscle cell hyperplasia via a p21 WAF1 -dependent pathway.

Wolf G. Renal injury due to renin-angiotensin-aldosterone system activation of the transforming growth factor-beta pathway. Kidney Int ; 70 — Bujak M, Frangogiannis NG. The role of TGF-beta signaling in myocardial infarction and cardiac remodeling. Tox U, Steffen HM. Impact of inhibitors of the renin—angiotensin—aldosterone system on liver fibrosis and portal hypertension. Losartan attenuates bleomycin-induced pulmonary fibrosis in rats.

Respiration ; 73 — Angiotensin II type 1 receptor blockade attenuates TGF-beta-induced failure of muscle regeneration in multiple myopathic states. Nat Med ; 13 — Thrombospondin 1 mediates angiotensin II induction of TGF-beta activation by cardiac and renal cells under both high and low glucose conditions. Dussaule JC, Chatziantoniou C.

Reversal of renal disease: is it enough to inhibit the action of angiotensin II? Cell Death Differ ; 14 — TGF-beta1: a novel target for cardiovascular pharmacology. Cytokine Growth Factor Rev ; 18 — Kidney Int Suppl ; 77 :S88—S Connective tissue growth factor expression and induction by transforming growth factor-beta is abrogated by simvastatin via a Rho signaling mechanism.

Simvastatin attenuates renal inflammation, tubular transdifferentiation and interstitial fibrosis in rats with unilateral ureteral obstruction. Nephrol Dial Transplant ; 20 — Antoniu SA.

Pirfenidone for the treatment of idiopathic pulmonary fibrosis. Expert Opin Investig Drugs ; 15 — Lasky J. IDrugs ; 7 — Inhibition of ALK5 signaling induces physeal dysplasia in rats.

Toxicol Pathol ; 35 — Antitumor effect of N -[3,4-dimethoxycinnamoyl]-anthranilic acid tranilast on experimental pancreatic cancer. J Nippon Med Sch ; 69 — Tranilast and cisplatin as an experimental combination therapy for scirrhous gastric cancer. Int J Oncol ; 13 — Effects of fibroblast growth inhibitor on proliferation and metastasis of oral squamous cell carcinoma.

Oral Oncol ; 39 — Antiangiogenic and antitumor effects of tranilast on mouse lung carcinoma cells. Int J Oncol ; 17 — Mehta JL, Attramadal H.

The TGFbeta superfamily in cardiovascular biology. Gewin, L. Lebrin, F. Das, R. Mack, M. Origin of myofibroblasts and cellular events triggering fibrosis. Chen, S. Yuan, W. Dennler, S. EMBO J. Piek, E. Goumans, M. Inazaki, K. Smad3 deficiency attenuates renal fibrosis, inflammation, and apoptosis after unilateral ureteral obstruction. Kim, J. Fujimoto, M.

Mice lacking Smad3 are protected against streptozotocin-induced diabetic glomerulopathy. Zhou, L. Mechanism of chronic aristolochic acid nephropathy: role of Smad3. Tsuchida, K. Yan, X. Shi, Y. Cell , — Fukasawa, H. Down-regulation of Smad7 expression by ubiquitin-dependent degradation contributes to renal fibrosis in obstructive nephropathy in mice. USA , — Chung, A.

Disruption of the Smad7 gene promotes renal fibrosis and inflammation in unilateral ureteral obstruction UUO in mice. Chen, H.

The protective role of Smad7 in diabetic kidney disease: mechanism and therapeutic potential. Diabetes 60 , — Liu, G. Hou, C. Ka, S. Smad7 gene therapy ameliorates an autoimmune crescentic glomerulonephritis in mice.

Diabetologia 55 , — Smad7 inhibits AngII-mediated hypertensive nephropathy in a mouse model of hypertension. Oncotarget 6 , — Ma, F.

Mitogen activated protein kinases in renal fibrosis. Google Scholar. Adhikary, L. Abnormal p38 mitogen-activated protein kinase signalling in human and experimental diabetic nephropathy. Diabetologia 47 , — De Borst, M. Glomerular and tubular induction of the transcription factor c-Jun in human renal disease. Stambe, C. A pathogenic role for c-Jun amino-terminal kinase signaling in renal fibrosis and tubular cell apoptosis.

Blockade of the c-Jun amino terminal kinase prevents crescent formation and halts established anti-GBM glomerulonephritis in the rat. Muller, R. Weigert, C. Diabetologia 45 , — Diabetes 49 , — Chuang, C. SB is required for high glucose-induced pro-fibrotic gene expression and hypertrophy in mesangial cells. Naito, T. Kamato, D. Lee, M. Sorrentino, A. Cell Biol. Chin, B.

Mariasegaram, M. Bakin, A. Wei, J. Hayashida, T. Tan, R. Hao, S. He, W. Poon, R. BMC Cell Biol. Amini Nik, S. Akhmetshina, A. Wang, D. Zhou, B. Eger, A.

Oncogene 23 , — Kim, K. Lam, A. Zeng, F. The role of the EGF family of ligands and receptors in renal development, physiology and pathophysiology. Liu, N. Genetic or pharmacologic blockade of EGFR inhibits renal fibrosis.

Yang, L. Chen, J. EGF receptor inhibition alleviates hyperuricemic nephropathy. Qian, Y. Novel epidermal growth factor receptor inhibitor attenuates angiotensin II-induced kidney fibrosis.

Zhuang, S. EGFR signaling in renal fibrosis. Samarakoon, R. Yan, Y. Src inhibition blocks renal interstitial fibroblast activation and ameliorates renal fibrosis. Lieberthal, W. Mammalian target of rapamycin and the kidney. The signaling pathway. Lamming, D. Rapamycin-induced insulin resistance is mediated by mTORC2 loss and uncoupled from longevity.

Science , — Pathophysiology and therapeutic implications. The role of the mammalian target of rapamycin mTOR in renal disease. Das, F. Li, J. Cordenonsi, M. Overstreet, J. Deshpande, S. Diabetes 62 , — Ghosh, A. The tumor suppressor p53 abrogates Smad-dependent collagen gene induction in mesenchymal cells. Li, R. Role of bone morphogenetic protein-7 in renal fibrosis. Zeisberg, M. Wang, S. Loss of tubular bone morphogenetic protein-7 in diabetic nephropathy.

Simon, M. Expression of bone morphogenetic protein-7 mRNA in normal and ischemic adult rat kidney. Hruska, K. Osteogenic protein-1 prevents renal fibrogenesis associated with ureteral obstruction. Renal bone morphogenetic protein-7 protects against diabetic nephropathy.

Bone morphogenic protein-7 inhibits progression of chronic renal fibrosis associated with two genetic mouse models. Motazed, R. BMP-7 and proximal tubule epithelial cells: activation of multiple signaling pathways reveals a novel anti-fibrotic mechanism. Veerasamy, M.

Munoz-Felix, J. Cytokine Growth Factor Rev. Scharpfenecker, M. Endoglin haploinsufficiency reduces radiation-induced fibrosis and telangiectasia formation in mouse kidneys. The role of endoglin in kidney fibrosis. Expert Rev. Goligorsky, M. Pathogenesis of endothelial cell dysfunction in chronic kidney disease: a retrospective and what the future may hold. Kidney Res. Rodriguez-Pena, A. Endoglin upregulation during experimental renal interstitial fibrosis in mice.

Hypertension 40 , — Roy-Chaudhury, P. Endoglin, a transforming growth factor-beta-binding protein, is upregulated in chronic progressive renal disease. Rodriguez-Barbero, A. Growth Fact. Hermida, N. A synthetic peptide from transforming growth factor-beta1 type III receptor prevents myocardial fibrosis in spontaneously hypertensive rats. Hocevar, B. TGF-beta induces fibronectin synthesis through a c-Jun N-terminal kinase-dependent, Smad4-independent pathway.

Hua, X. Synergistic cooperation of TFE3 and smad proteins in TGF-beta-induced transcription of the plasminogen activator inhibitor-1 gene. Genes Dev. Ignotz, R. Transforming growth factor-beta stimulates the expression of fibronectin and collagen and their incorporation into the extracellular matrix. Google Scholar.

Inman, G. Jiang, D. Inhibition of pulmonary fibrosis in mice by CXCL10 requires glycosaminoglycan binding and syndecan Ketteler, M. Increased expression of transforming growth factor-beta in renal disease. Khan, S. Enhanced bioactive myocardial transforming growth factor-beta in advanced human heart failure. Li, J. Blockade of endothelial-mesenchymal transition by a Smad3 inhibitor delays the early development of streptozotocin-induced diabetic nephropathy.

Diabetes Metab. Li, S. Li, R. Role of bone morphogenetic protein-7 in renal fibrosis. Li, Z. Myostatin directly regulates skeletal muscle fibrosis. Lijnen, P. Transforming growth factor-beta 1 promotes contraction of collagen gel by cardiac fibroblasts through their differentiation into myofibroblasts.

Methods Find. Induction of cardiac fibrosis by transforming growth factor-beta 1. Llopiz, D. Peptide inhibitors of transforming growth factor-beta enhance the efficacy of antitumor immunotherapy. Cancer , — Lopez-Dee, Z. Thrombospondin multiple paths to inflammation. Mediators Inflamm. Ludviksson, B. Transforming growth factor-beta as a regulator of site-specific T-cell inflammatory response. Lv, Q. The advancements of heparanase in fibrosis.

Lyons, R. Mechanism of activation of latent recombinant transforming growth factor beta 1 by plasmin. Macneal, K. The genetic and environmental causes of pulmonary fibrosis. Margadant, C. Integrin-TGF-beta crosstalk in fibrosis, cancer and wound healing. EMBO Rep. Masola, V. Acta , — Mead, A. Evaluation of anti-TGF-beta2 antibody as a new postoperative anti-scarring agent in glaucoma surgery.

Mendell, J. Follistatin gene therapy for sporadic inclusion body myositis improves functional outcomes. Meng, X. TGF-beta: the master regulator of fibrosis.

Milani, S. Transforming growth factors beta 1 and beta 2 are differentially expressed in fibrotic liver disease. Miyazawa, K. Two major Smad pathways in TGF-beta superfamily signalling. Genes Cells 7, — Molina-Molina, M. Quantifying plasma levels of transforming growth factor beta1 in idiopathic pulmonary fibrosis.

Morissette, M. Effects of myostatin deletion in aging mice. Aging Cell 8, — Morris, D. Loss of integrin alpha v beta6-mediated TGF-beta activation causes Mmpdependent emphysema. Nature , — Munger, J. The integrin alpha v beta 6 binds and activates latent TGF beta 1: a mechanism for regulating pulmonary inflammation and fibrosis.

Cell 96, — Munoz-Felix, J. Identification of bone morphogenetic protein 9 BMP9 as a novel profibrotic factor in vitro. Where have we arrived after 25 years of trials and tribulations? Murakami, M. Transcriptional regulation of plasminogen activator inhibitor-1 by transforming growth factor-beta, activin A and microphthalmia-associated transcription factor. Nagy, P. Immunohistochemical detection of transforming growth factor-beta 1 in fibrotic liver diseases.

Hepatology 14, — Nikolic-Paterson, D. Interleukin-1 in renal fibrosis. Noble, P. Occleston, N. Prevention and reduction of scarring in the skin by Transforming Growth Factor beta 3 TGFbeta3 : from laboratory discovery to clinical pharmaceutical. Ohga, E. Effects of activin A on proliferation and differentiation of human lung fibroblasts. Interleukin-6, its role in fibrosing conditions.

Cytokine Growth Factor. Ota, F. Activin A induces cell proliferation of fibroblast-like synoviocytes in rheumatoid arthritis. Arthritis Rheum. Patella, S. Follistatin attenuates early liver fibrosis: effects on hepatic stellate cell activation and hepatocyte apoptosis. Liver Physiol. Petersen, M. Popov, Y. Integrin alphavbeta6 is a marker of the progression of biliary and portal liver fibrosis and a novel target for antifibrotic therapies.

Presser, L. Qiao, C. Myostatin propeptide gene delivery by adeno-associated virus serotype 8 vectors enhances muscle growth and ameliorates dystrophic phenotypes in mdx mice. Gene Ther. Roberts, A. Transforming growth factor type beta: rapid induction of fibrosis and angiogenesis in vivo and stimulation of collagen formation in vitro. Rodgers, B. Myostatin stimulates, not inihibits, C2C12 myoblast proliferation.

Endocrinology , — Romaris, M. Effect of transforming growth factor-beta 1 and basic fibroblast growth factor on the expression of cell surface proteoglycans in human lung fibroblasts. Enhanced glycanation and fibronectin-binding of CD44 proteoglycan, and down-regulation of glypican.